POEMS syndrome is extremely rare, with an estimated incidence of about 0.3 cases per 100,000 people. To put that in perspective, in a city of one million people, only three new cases would be expected in a given year. Its rarity is one reason it’s frequently misdiagnosed, with roughly 60% of patients initially told they have a different nerve condition before receiving the correct diagnosis.
What POEMS Syndrome Is
POEMS is an acronym for the constellation of problems the syndrome can cause: polyneuropathy (nerve damage), organomegaly (enlarged organs), endocrinopathy (hormone imbalances), M-protein (an abnormal protein in the blood), and skin changes. It’s classified as a paraneoplastic syndrome, meaning it’s driven by an underlying issue with plasma cells, a type of immune cell. In nearly all cases, the abnormal plasma cells produce a specific kind of antibody fragment called a lambda light chain.
One of the key biological drivers is dramatically elevated levels of a protein that promotes blood vessel growth. In people with POEMS, blood levels of this protein typically reach a median of around 4,000 pg/mL, far above the normal range. That overproduction is thought to be responsible for many of the widespread symptoms, from nerve damage to fluid buildup.
Who Gets It
POEMS syndrome affects men far more often than women, at a ratio of roughly 4 to 1 in published cohorts. The median age at diagnosis is around 49 to 57, depending on the study population, making it primarily a disease of middle age. It can occur outside that window, with transplant data showing patients ranging from their mid-20s to late 60s, but it’s uncommon in younger adults and rare in children.
Why It’s So Often Misdiagnosed
The most prominent early symptom for most patients is a progressive, symmetrical nerve problem that causes numbness, tingling, and weakness in the hands and feet. This pattern closely mimics a much more common condition called chronic inflammatory demyelinating polyneuropathy (CIDP), and about 60% of POEMS patients are initially misdiagnosed with CIDP as a result. The distinction matters enormously because the treatments are completely different, and delays can allow significant, sometimes irreversible, neurological damage to accumulate.
Several clues can help distinguish the two. POEMS patients often have additional features that CIDP patients don’t: unusually thickened or darkened skin, swollen lymph nodes or an enlarged liver or spleen, hormonal problems like thyroid dysfunction or low testosterone, and unexplained fluid retention. If someone diagnosed with CIDP isn’t improving with standard immune treatments, or if they develop these extra symptoms, POEMS should be considered.
How It’s Diagnosed
Diagnosis requires meeting a specific set of criteria. Two features must always be present: a polyneuropathy (nerve damage confirmed on testing) and evidence of a clonal plasma cell disorder (the abnormal M-protein). Beyond those two mandatory findings, at least one more major criterion is needed from the following group: bone lesions that appear dense or “sclerotic” on imaging, markedly elevated levels of the blood vessel growth protein, or the presence of Castleman disease (a related lymph node disorder that overlaps with POEMS in 11% to 30% of cases).
On top of meeting three major criteria, at least one minor criterion must also be present. Minor criteria include organ enlargement, hormone abnormalities, characteristic skin changes, swelling of the optic nerve (papilledema), fluid overload outside the blood vessels, and an elevated platelet count. Because so many organ systems can be involved, patients often see multiple specialists before anyone connects the dots.
Treatment and What to Expect
There is no single established standard of care for POEMS syndrome, and no randomized controlled trials have determined the best approach. Treatment strategies are largely adapted from related blood cancers like myeloma.
For patients healthy enough to tolerate it, a stem cell transplant is one of the most studied options. Data from a large European registry of 127 transplant patients showed encouraging results: 90% were alive at a median follow-up of four years, and the five-year overall survival probability was 89%. About half of patients achieved a complete blood response, though relapse remains common even after transplant, with roughly 16.5% of patients experiencing disease progression during follow-up.
For patients who aren’t transplant candidates, or as a bridge before transplant, drug combinations that target the abnormal plasma cells are used. In one prospective study of 18 patients treated with a combination regimen, 72% responded, though only half showed both measurable blood improvement and meaningful neurological recovery. The neurological response tends to lag behind the blood response by months, so patience is important during treatment.
Long-Term Survival
POEMS syndrome is serious but not typically fatal in the near term with appropriate treatment. In a study of patients who received first-line drug therapy, the five-year overall survival rate was approximately 89%, and the three-year rate was 90%. Progression-free survival is lower, with about 75% of patients free of progression at three years and 55% at five years, reflecting the tendency of the disease to relapse or require additional treatment over time.
The gap between overall survival and progression-free survival tells an important story: many patients who relapse can be treated again successfully. The disease often follows a pattern of treatment, remission, eventual relapse, and retreatment rather than a single course that either works or doesn’t. Nerve damage already present at diagnosis may only partially recover, which is why earlier diagnosis translates directly into better functional outcomes. The months or years lost to misdiagnosis as CIDP can have lasting consequences for mobility and quality of life.